MLTX News and Press, MoonLake Immunotherapeutics

HCI Group Inc. (HCI) is expected to report $4.87 for Q4 2025 XPEL Inc. (XPEL) is expected to report $0.43 for Q4 2025 Oversea-Chinese Banking Corporation Limited ADR (OVCHY) is expected to report $0.56 for Q4 2025 UMH Properties Inc. (UMH) is expected to report $0.24 for Q4 2025 I...

MoonLake Immunotherapeutics (MLTX) is expected to report $-0.97 for Q4 2025

2026-02-24 13:50:12 ET The last time I wrote an article on MoonLake Immunotherapeutics ( MLTX ), it was in a Seeking Alpha article entitled " MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest. " At that time, things were looking very good for th...

2026-02-24 08:03:55 ET from Oppenheimer issued a price target of $35.00 for MLTX on 2026-02-24 12:50:01. The adjusted price target was set to $35.00. At the time of the announcement, MLTX was trading at $18.68. The overall price target consensus is at $19.25 with high pr...

2026-02-23 15:34:29 ET More on Lemonade: AI Is A Net Tailwind As 2027 Profitability Remains In Sight Chinese Stocks And The FXI After The Supreme Court Ruling On U.S. Tariffs MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript Top performing so...

2026-02-23 15:24:57 ET MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day February 23, 2026 8:00 AM EST... Read the full article on Seeking Alpha For further details see: MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript

In the Phase 2 S-OLARIS clinical trial in axial spondyloarthritis (axSpA), sonelokimab (SLK) demonstrated clinically meaningful benefit with 80+% of patients achieving ASAS40 by Week 12 Consistently, other clinical and imaging scores also showed improvements of 80+% by week 12 for patients tre...

Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene’s clinical organization and drive completion of the Phase 2b ADAPTIVE trial in atopic dermatitis Will expand Phase 2b tri...

2026-02-02 09:20:34 ET More on MoonLake Immunotherapeutics MoonLake: Positive FDA Meeting Spurs Momentum Ahead Of BLA Submission MoonLake: Ignore The Panic, Catch The Upside MoonLake cut to sell at Goldman Sachs on risks to lead asset’s approval MoonLa...

The Dermatology Division of the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sonelokimab (SLK) in moderate-to-severe  palmoplantar pustulosis (PPP) supported by positive results from the Phase 2 LEDA trial The upcoming Phase 3 program will therefore be ex...